Epizyme
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Epizyme sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Epizyme: 16 sponsored US clinical trials, 2 recruiting.
Epizyme sponsors 16 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 10 completed. 1 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malignant Rhabdoid Tumor of Ovary, with 1 trials.
Top-decile sponsor footprint
Epizyme ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (71.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
16 total, page 1 of 1
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
NCT04224493
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
NCT04241835
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT05121103
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
NCT04762160
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
NCT04537715
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
NCT04204941
A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer
NCT04179864
Epithelioid Sarcoma Natural History Study
NCT03837678
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
NCT03028103
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
NCT02875548
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
NCT02860286
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
NCT02601937
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
NCT02601950
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
NCT02141828
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
NCT01897571
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
NCT01684150
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 3 |
| Phase 3 | 1 |
What is open in the Epizyme pipeline
2 recruiting of 16 indexed (13% open); 10 completed (63%).
Phase mix: 1 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Malignant Rhabdoid Tumor of Ovary (1 trial), 8 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Epizyme: open-pipeline peers nationwide
Peers matched on 16 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
Epizyme sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
- Avidity Biosciences · 13% recruiting · 8 trials
Related
What to do with this Epizyme page
16 registered trials is a research-attention snapshot, not an endorsement of Epizyme or any single study.
- 2 of Epizyme's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Malignant Rhabdoid Tumor of Ovary is the condition Epizyme studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malignant Rhabdoid Tumor of Ovary trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Epizyme pipeline card: 16 registered trials from official public datasets.Report a data error.